Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T01:29:27.749Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing Genetic Technologies: Two Ethical Issues

Published online by Cambridge University Press:  10 March 2009

Thomas H. Murray
Thomas H. Murray
Affiliation:
Case Western Reserve University
Get access Rights & Permissions [Opens in a new window]

Abstract

Assessment of the impact of genetic technologies requires an understanding of the ethical issues that such technologies raise, which in turn requires an understanding of the social context of genetics. This article discusses 10 factors that characterize the social context of contemporary genetics, and considers two presumptions that usually are unquestioned—first, that more choice is always better; second, that what can be improved should be improved. Recent experience with genetic screening and testing to increase reproductive choice indicates that it is sometimes an ambiguous good. Prenatal testing, which has been guided by an ideology of nondirective counseling, will become increasingly problematic as the menu of possible genetic tests grows longer, because nondirectiveness offers no way to distinguish between significant disease and parental whim. In the realm of reproduction, more choice may also come to mean increasing parental responsibility to have genetically “healthy” offspring. Technologies intended to improve health outcomes may also be used for non-health-related goals—such as to increase athletic performance or to capitalize on social prejudices. Genetic technologies increasingly will challenge the troubled distinction between therapy and enhancement.

Type
Special Section: Genetic Technology
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 4 , Fall 1994 , pp. 573 - 582
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Angastiniotis, M., Kyriakidou, S., & Hadjiminas, M.How thalassemia was controlled in Cyprus. World Health Forum, 1986, 7, 291–97.Google Scholar
2.Holtzman, N. A.Proceed with caution: Predicting genetic risks in the recombinant DN era. Baltimore, MD: Johns Hopkins University Press, 1989.Google Scholar
3.Loukopoulos, D., Kaltsoya-Tassiopoulou, A., & Fessas, P.Thalassemia control in Greece. Birth Defects: Original Article Series, 1988, 23(5B), 405–16.Google ScholarPubMed
4.Murray, T. H.The growing danger from gene-spliced hormones. Discover, 1987, 8, 88–92.Google ScholarPubMed
5.Murray, T. H. The Human Genome Project and genetic testing: Ethical implications. In Frankel, M.s. & Teich, A. H. (eds.), The Genome, ethics and law: Issues in genetic testing. Washington, DC: American Association for the Advancement of Science, 1992, 49–78.Google Scholar
6.Wilfond, B. S., & Fost, N.The cystic fibrosis gene: Medical and social implications for heterozygote detection. Journal of the American Medical Association, 1990, 263, 2777–83.CrossRefGoogle ScholarPubMed